Mesoblast’s allogeneic or ‘off-the-shelf’ regenerative medicine products focus on repair of damaged tissues and modulation of inflammatory responses in conditions with significant unmet medical needs.
Mesoblast’s cell-based core technologies include its highly purified, immunoselected Mesenchymal Precursor Cells (MPCs), culture-expanded Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs). Mesoblast’s protein technologies are based on factors derived from its proprietary cellular platforms, including Stromal Derived Factor-1 (SDF-1).
Mesoblast is developing a range of products derived from the Company’s proprietary Mesenchymal Cell Lineage technology platforms. Mesoblast’s product development focus is in four major and distinct areas:
Latest NewsView all announcements
- 5-9 June 2015 - Poster presentation on initial diabetic nephropathy results, late-breaking scientific sessions, 75th American Diabetes Association annual meeting, Boston, MA.